What if the future of colorectal cancer screening didn’t require a scope… or even stool?
A new study in The American Journal of Gastroenterology suggests that an AI-driven fragmentomics blood test from GC Genome may detect:
• >90% of colorectal cancers
• Early-stage disease (including T1N0, eligible for endoscopic cure)
• Precancerous adenomas — something most blood tests fail to do
Even more surprising? Performance stayed strong regardless of tumor location or patient age — a known blind spot for many technologies.
Is this an alternative pathway for early CRC prevention — or another test competing for limited screening attention?